Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 4/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830844 | 0.92 | ATM (0.42) | CNR2NAMPTGPR119CNR1MEN1 | |
| SCHEMBL21180420 | 0.87 | PKM (0.42) | CNR2NAMPTGPR119CNR1HDAC1 | |
| SCHEMBL17830843 | 0.84 | GPR119 (0.40) | CNR2NAMPTGPR119CNR1MEN1 | |
| SCHEMBL12723192 | 0.74 | CYP3A4 (0.48) | GPR119MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL12480371 | 0.72 | GPR119 (0.56) | GPR119ATM | |
| SCHEMBL23108170 | 0.71 | GPR119 (0.51) | GPR119ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL28614518 | 0.71 | CYP11B2 (0.51) | GPR119NPSR1ACACBATM | |
| SCHEMBL32679621 | 0.69 | ACACB (0.46) | GPR119NPSR1ACACBATM | |
| SCHEMBL16644394 | 0.69 | ATM (0.46) | NAMPTGPR119MEN1ALDH1A1LMNA | |
| SCHEMBL26832679 | 0.69 | RAB9A (0.46) | GPR119MEN1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10358421-B2 | Piperidine derivatives as HDAC1/2 inhibitors | HDAC1, HDAC2, HDAC10 | CNR2 3412/4885NAMPT 839/4885GPR119 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.